Judith Klimovsky
Director/Board Member presso BIO-TECHNE CORPORATION
Patrimonio netto: 3 M $ in data 31/03/2024
Posizioni attive di Judith Klimovsky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| GENMAB A/S | Corporate Officer/Principal | 09/02/2017 | - |
| BIO-TECHNE CORPORATION | Director/Board Member | 24/04/2024 | - |
| Independent Dir/Board Member | 24/04/2024 | - |
Storia della carriera di Judith Klimovsky
Precedenti posizioni note di Judith Klimovsky
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| BELLICUM PHARMACEUTICALS, INC. | Director/Board Member | 20/12/2018 | 23/02/2024 |
| NOVARTIS AG | Corporate Officer/Principal | 01/05/2009 | 01/02/2017 |
Novartis Pharma AG
 Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Corporate Officer/Principal | 01/01/2009 | 01/01/2017 |
Formazione di Judith Klimovsky
| University of Buenos Aires School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 3 |
| Svizzera | 3 |
| Danimarca | 2 |
Posizioni
| Corporate Officer/Principal | 3 |
| Director/Board Member | 2 |
| Doctorate Degree | 1 |
Settori
| Health Technology | 6 |
| Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Società quotate in Borsa | 3 |
|---|---|
| BIO-TECHNE CORPORATION | Health Technology |
| NOVARTIS AG | Health Technology |
| GENMAB A/S | Health Technology |
| Aziende private | 2 |
|---|---|
Bellicum Pharmaceuticals, Inc.
 Bellicum Pharmaceuticals, Inc. BiotechnologyHealth Technology Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It focuses on discovering and developing cellular immunotherapies for cancers and orphan inherited blood disorders. The firm uses its proprietary chemical induction of dimerization that controls components of the immune system in real time. Its product candidates include BPX-601, BPX-603, and Rivo-cel (rivogenlecleucel, formerly known as BPX-501). The company was founded by Kevin M. Slawin and David M. Spencer on July 14, 2004 and is headquartered in Houston, TX. | Health Technology |
Novartis Pharma AG
Novartis Pharma AG Pharmaceuticals: MajorHealth Technology Novartis Pharma AG engages in the research in as well as the production and distribution of pharmaceutical, chemical, medical, and biotechnological products. It also provides related services. The company was founded on October 25, 1989 and is headquartered in Basel, Switzerland. | Health Technology |
- Borsa valori
- Insiders
- Judith Klimovsky
- Esperienza
